Nifty
:
23727.65
Sensex
:
78472.87
-25.80 (-0.11%)
-67.30 (-0.09%)
Nifty
Sensex
:
:
23727.65
78472.87
-25.80 (-0.11%)
-67.30 (-0.09%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 500257 | NSE: LUPIN

NSE BSE
2169.45
24-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  2170.00
  •  2186.50
  •  2150.00
  •  2160.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  499489
  •  10852.01
  •  2312.00
  •  1266.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 98,555.79
  • 37.52
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,00,313.92
  • 0.37%
  • 6.30

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.96%
  • 0.32%
  • 5.29%
  • FII
  • DII
  • Others
  • 21.5%
  • 24.10%
  • 1.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.59
  • 3.51
  • 6.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 8.90
  • 77.47

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.25
  • 26.17
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.40
  • 36.05
  • 40.85

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.48
  • 3.68
  • 3.93

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.04
  • 17.70
  • 17.25

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
42.05
67.26
83.17
84.98
P/E Ratio
47.71
29.83
24.12
23.61
Revenue
19656
22372
25033
26518
EBITDA
3800
4989
5950
6161
Net Income
1914
3072
3740
3975
ROA
8.2
13.3
15.9
14.4
P/Bk Ratio
6.4
5.42
4.54
3.89
ROE
14.31
19.59
20.4
17.62
FCFF
2482.79
2038.49
3229.36
3633.8
FCFF Yield
2.64
2.17
3.43
3.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
5,672.73
5,038.56
12.59%
5,600.33
4,814.06
16.33%
4,960.79
4,430.08
11.98%
5,197.41
4,322.22
20.25%
Expenses
4,332.37
4,120.80
5.13%
4,359.36
3,957.77
10.15%
3,964.03
3,852.31
2.90%
4,175.45
3,806.18
9.70%
EBITDA
1,340.36
917.76
46.05%
1,240.97
856.29
44.92%
996.76
577.77
72.52%
1,021.96
516.04
98.04%
EBIDTM
23.63%
18.21%
22.16%
17.79%
20.09%
13.04%
19.66%
11.94%
Other Income
42.29
40.40
4.68%
67.78
22.83
196.89%
29.34
37.27
-21.28%
45.35
34.59
31.11%
Interest
70.87
80.64
-12.12%
68.01
85.67
-20.61%
71.29
92.55
-22.97%
74.01
84.09
-11.99%
Depreciation
256.92
247.85
3.66%
247.71
234.66
5.56%
457.10
263.99
73.15%
257.20
220.40
16.70%
PBT
1,054.86
629.67
67.53%
993.03
558.79
77.71%
497.71
258.50
92.54%
736.10
246.14
199.06%
Tax
195.38
134.35
45.43%
187.49
105.46
77.78%
129.49
16.11
703.79%
117.40
88.49
32.67%
PAT
859.48
495.32
73.52%
805.54
453.33
77.69%
368.22
242.39
51.91%
618.70
157.65
292.45%
PATM
15.15%
9.83%
14.38%
9.42%
7.42%
5.47%
11.90%
3.65%
EPS
18.69
10.76
73.70%
17.57
9.94
76.76%
7.89
5.19
52.02%
13.46
3.37
299.41%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
21,431.26
20,010.82
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
Net Sales Growth
15.19%
20.25%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
 
Cost Of Goods Sold
6,734.42
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
Gross Profit
14,696.84
14,366.16
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
GP Margin
68.58%
71.79%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
Total Expenditure
16,831.21
16,221.71
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
Power & Fuel Cost
-
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
% Of Sales
-
2.46%
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
Employee Cost
-
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
% Of Sales
-
17.46%
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
Manufacturing Exp.
-
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
% Of Sales
-
13.68%
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
General & Admin Exp.
-
2,221.17
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
% Of Sales
-
11.10%
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
Selling & Distn. Exp.
-
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
% Of Sales
-
6.71%
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
Miscellaneous Exp.
-
286.55
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
835.48
% Of Sales
-
1.43%
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
EBITDA
4,600.05
3,789.11
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
EBITDA Margin
21.46%
18.94%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
Other Income
184.76
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
Interest
284.18
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
Depreciation
1,218.93
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
PBT
3,281.70
2,422.27
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
Tax
629.76
486.70
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
Tax Rate
19.19%
20.09%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
PAT
2,651.94
1,914.48
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
PAT before Minority Interest
2,626.49
1,935.57
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
Minority Interest
-25.45
-21.09
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
PAT Margin
12.37%
9.57%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
PAT Growth
96.63%
345.15%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
 
EPS
58.14
41.98
9.43
-33.50
26.64
-6.00
13.41
5.43
55.89
49.46
52.69

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
Share Capital
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
Total Reserves
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
Non-Current Liabilities
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
Secured Loans
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
Unsecured Loans
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
Long Term Provisions
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
Current Liabilities
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
Trade Payables
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
Other Current Liabilities
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
Short Term Borrowings
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
Short Term Provisions
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
Total Liabilities
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
Net Block
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
Gross Block
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
Accumulated Depreciation
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
Non Current Assets
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
Capital Work in Progress
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
Non Current Investment
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
Long Term Loans & Adv.
277.52
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
Other Non Current Assets
90.95
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
Current Assets
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
Current Investments
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
Inventories
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
Sundry Debtors
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
Cash & Bank
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
Other Current Assets
1,752.23
1,519.98
497.54
556.89
1,717.86
1,769.95
1,711.95
1,191.01
1,241.22
534.98
Short Term Loans & Adv.
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
Net Current Assets
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
Total Assets
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
PBT
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
Adjustment
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
Changes in Working Capital
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
Cash after chg. in Working capital
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
Net Fixed Assets
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
Net Investments
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
Others
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
Cash from Financing Activity
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
Net Cash Inflow / Outflow
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
Opening Cash & Equivalents
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
Closing Cash & Equivalent
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
ROA
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
ROE
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
ROCE
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
Fixed Asset Turnover
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
Receivable days
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
Inventory Days
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
Payable days
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
Cash Conversion Cycle
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
Total Debt/Equity
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
Interest Cover
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Lupin gets USFDA’s nod for Emtricitabine and Tenofovir Alafenamide Tablets
    19th Dec 2024, 11:29 AM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin’s arm recalling over 6 lakh bottles of Ramipril capsules in US
    26th Nov 2024, 14:40 PM

    The affected lot is manufactured at Lupin's Goa-based manufacturing facility

    Read More
  • Lupin reports 74% rise in Q2 consolidated net profit
    8th Nov 2024, 14:28 PM

    Total consolidated income of the company increased by 12.52% at Rs 5715.02 crore for Q2FY25

    Read More
  • Lupin - Quarterly Results
    7th Nov 2024, 18:34 PM

    Read More
  • Lupin launches first generic version of Pred Forte in United States
    15th Oct 2024, 14:26 PM

    Pred Forte had estimated annual sales of $198 million in the U.S. (IQVIA MAT August 2024)

    Read More
  • USFDA completes pre-approval inspection at Lupin’s Biotech facility in Pune
    7th Oct 2024, 09:29 AM

    The inspection was carried out from September 25, 2024 to October 4, 2024, and concluded with five observations

    Read More
  • Lupin inks distribution pact with Scope Ophthalmics
    1st Oct 2024, 11:42 AM

    Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America

    Read More
  • USFDA inspects Lupin’s manufacturing facility at Pithampur Unit-1
    28th Sep 2024, 16:02 PM

    The inspection closed with three observations each on the API and Finished Product side

    Read More
  • Lupin enters into non-exclusive patent license agreement with Takeda
    18th Sep 2024, 14:59 PM

    Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.